What is HC Wainwright’s Estimate for LGND FY2025 Earnings?

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) – Equities research analysts at HC Wainwright lifted their FY2025 EPS estimates for shares of Ligand Pharmaceuticals in a report issued on Wednesday, December 11th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings per share of $3.46 for the year, up from their prior forecast of $3.23. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Ligand Pharmaceuticals’ current full-year earnings is $1.73 per share.

LGND has been the subject of a number of other research reports. Royal Bank of Canada raised their target price on shares of Ligand Pharmaceuticals from $141.00 to $143.00 and gave the stock an “outperform” rating in a research note on Wednesday. Benchmark lifted their price objective on shares of Ligand Pharmaceuticals from $110.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Barclays lifted their price objective on shares of Ligand Pharmaceuticals from $125.00 to $150.00 and gave the stock an “overweight” rating in a research note on Friday, November 8th. Finally, Oppenheimer lifted their price objective on shares of Ligand Pharmaceuticals from $135.00 to $147.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $145.33.

Ligand Pharmaceuticals Stock Performance

NASDAQ LGND opened at $113.51 on Friday. The firm has a 50-day moving average of $113.76 and a 200-day moving average of $101.88. The stock has a market cap of $2.15 billion, a PE ratio of 45.22 and a beta of 1.01. Ligand Pharmaceuticals has a 52-week low of $62.83 and a 52-week high of $129.90.

Insider Activity at Ligand Pharmaceuticals

In other Ligand Pharmaceuticals news, insider Andrew Reardon sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $99.60, for a total transaction of $199,200.00. Following the sale, the insider now directly owns 22,534 shares of the company’s stock, valued at $2,244,386.40. The trade was a 8.15 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John L. Lamattina sold 2,406 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $123.65, for a total transaction of $297,501.90. Following the sale, the director now directly owns 29,515 shares in the company, valued at $3,649,529.75. The trade was a 7.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 21,728 shares of company stock valued at $2,271,575. 5.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Ligand Pharmaceuticals

A number of institutional investors have recently modified their holdings of LGND. Innealta Capital LLC bought a new stake in shares of Ligand Pharmaceuticals in the 2nd quarter valued at $31,000. Rothschild Investment LLC bought a new stake in shares of Ligand Pharmaceuticals in the 2nd quarter valued at $34,000. Headlands Technologies LLC boosted its stake in shares of Ligand Pharmaceuticals by 21.7% in the 2nd quarter. Headlands Technologies LLC now owns 758 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 135 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Ligand Pharmaceuticals by 23.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 661 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 125 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. bought a new stake in shares of Ligand Pharmaceuticals in the 2nd quarter valued at $67,000. 91.28% of the stock is owned by institutional investors.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.